Clinical trials: Antiviral Agents
Hepatitis B, Chronic Hepatitis B
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection
- Trial name
- NCT02826018
- Testing
- ALN-HBV, Sterile Normal Saline (0.9% NaCl)
- Where
- 9 sites in Australia, Hong Kong and 4 more
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Chronic Hepatitis B
Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the reasonable dosage of HRS-5635.
- Trial name
- NCT05808374
- Testing
- HRS-5635
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hepatitis B, Chronic
Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity
Hepatitis B virus (HBV) leads to life-threatening disease like liver failure and liver cancer. For most, a cure is unattainable as current HBV antiviral therapy (using nucleoside analogues) are not able to clear the virus from…
- Trial name
- NCT03759782
- Testing
- Ribavirin, Tenofovir
- Where
- 2 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Ottawa Hospital Research Institute
HIV Infections
The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs
To compare the durability of the viral load response following 48 weeks of treatment with 1592U89/lamivudine (3TC)/zidovudine (ZDV) versus 3TC/ZDV alone.
- Trial name
- NCT00002389
- Testing
- Abacavir sulfate, Lamivudine, Zidovudine
- Where
- 15 sites in United States, Canada and 1 more
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus, HIV-1 Infection
Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults
To investigate safety, tolerability and anti-viral activity in Integrase-Naïve HIV-1 infected adults
- Trial name
- NCT00398125
- Testing
- GSK364735
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Human Immunodeficiency Virus
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
This is a 28-day, multi-center, placebo-controlled study designed to look at the dose response, efficacy, and safety of SP01A, given as a pill to be swallowed, in the treatment of HIV-infected subjects.
- Trial name
- NCT00299897
- Testing
- SP01A
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samaritan Pharmaceuticals, Inc
HIV-1, HIV Infections
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents
The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), safety, tolerability and antiviral activity to support dose recommendations of TMC114…
- Trial name
- NCT00355524
- Testing
- TMC114, Ritonavir
- Where
- 22 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
SARS-CoV-2 Infection
A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
- Trial name
- SCORPIO-HR (NCT05305547)
- Testing
- S-217622
- Where
- 196 sites in United States, Argentina and 15 more
- Volunteers
- 2,093 people
- Sponsor
- Shionogi
HBV, Chronic Hepatitis b
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
This is a multicenter, prospective, real-world study. The study plans to include a total of 2000 patients who meet the inclusion and exclusion criteria, consisting of 1600 treatment-naive patients and 400 treatment-experienced…
- Trial name
- NCT06926647
- Testing
- Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα
- Where
- 85 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing 302 Hospital
Dengue, Antiviral Drugs
Adaptive Dengue Antiviral Platform Trial
This is a randomized, open-label adaptive platform trial aiming to screen the antiviral effectiveness of the experimental drug(s) in early dengue infection Primary objectives: To determine the antiviral effectiveness of the…
- Trial name
- ADAPT (NCT06551844)
- Testing
- Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg
- Where
- 2 sites in Malaysia, Vietnam
- Volunteers
- 500 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Infectious Disease
Phase 2, Multiple Ascending Dose Proof of Concept Study
This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.
- Trial name
- NCT02710604
- Testing
- CMX157, TDF
- Where
- Thailand
- Volunteers
- 62 people
- Sponsor
- ContraVir Pharmaceuticals, Inc.
Influenza, Severe Acute Respiratory Distress Syndrome
Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study
This study will examine the safety of an experimental medication called Poly-ICLC, developed for preventing or reducing the severity of infections from influenza and other viruses acquired through the nose, mouth and lungs.
- Conditions
- Influenza, Severe Acute Respiratory Distress Syndrome, Smallpox, Ebola
- Trial name
- NCT00646152
- Testing
- Poly-ICLC
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Safety and Effectiveness of 935U83 in HIV-Infected Patients
To assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of 935U83 administered to patients with HIV infection. To obtain preliminary evidence of antiretroviral activity of 935U83.
- Trial name
- NCT00002338
- Testing
- Raluridine
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Glaxo Wellcome
Chronic Hepatitis B
Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus
This trial will study the effect of a polyherbal capsule in lowering the viral load of patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B surface antigen elimination in 12 months
- Trial name
- NCT02899130
- Testing
- Polyherbal
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Composite Interceptive Med Science
Uterine Cervical Neoplasia, Cervix Intraepithelial Neoplasia
Safety and Efficacy Study of Antiviral Local Application to Treat High Grade Cervical Intraepithelial Lesions (CIN2/3)
The purpose of this phase-II study is to evaluate the efficacy and safety of an aqueous gel containing an antiviral, administered directly on cervix exhibiting high grade squamous or glandular intraepithelial lesion (CIN 2 and 3)…
- Trial name
- Colvir-PhaseII (NCT01303328)
- Testing
- C1
- Where
- 9 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- Mithra Pharmaceuticals
Metapneumovirus
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
The purpose of this study is to determine in hospitalized adult participants infected with human metapneumovirus (hMPV - a virus closely related to respiratory syncytial virus (RSV) and has been identified as an important cause…
- Trial name
- STEP (NCT03502694)
- Testing
- Lumicitabine
- Where
- 112 sites in United States, Argentina and 14 more
- Sponsor
- Janssen Research & Development, LLC
COVID-19
Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)
The trial will develop and validate a platform for quantitative assessment of antiviral effects in low-risk patients with high viral burdens and uncomplicated COVID-19 to determine in-vivo antiviral activity.
- Trial name
- PLATCOV (NCT05041907)
- Testing
- Nirmatrelvir/ritonavir (e.g. PAXLOVID™), Nitazoxanide, Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
- Where
- 7 sites in Brazil, Laos and 3 more
- Volunteers
- 3,800 people
- Sponsor
- University of Oxford
Hepatitis C, Chronic
An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens
This observational long-term follow-up study will assess the persistence of direct acting antiviral (DAA) resistant mutations and the durability of sustained virological response in patients with chronic hepatitis C who have…
- Trial name
- NCT01168856
- Where
- 126 sites in United States, Australia and 13 more
- Volunteers
- 734 people
- Sponsor
- Hoffmann-La Roche
Bioequivalence
The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions
A single dose of Reference product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride and a single dose of Test product containing 200 mg umifenovir hydrochloride monohydrate…
- Trial name
- Umifenovir (NCT04476719)
- Testing
- ATAFENOVIR 200 MG KAPSUL, ARBIDOL 100 MG KAPSUL
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Atabay Kimya Sanayi Ticaret A.S.
Hepatitis C, Chronic
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
This study will evaluate the efficacy and safety of 4 regimens of PEGASYS plus Copegus, in patients with chronic hepatitis C (CHC) genotype 1 who have failed to respond to previous treatment with standard doses of PEGASYS plus…
- Trial name
- NCT00412334
- Testing
- Copegus, peginterferon alfa-2a [Pegasys]
- Where
- 22 sites in France
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.